Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. Co. provides a suite of products for the treatment of structural and non-structural causes of abnormal uterine bleeding in most uterine anatomies. Co.'s devices are used by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. Co.'s product offerings include Minerva ES Endometrial Ablation System; Genesys HTA Endometrial Ablation System; Symphion Tissue Removal System; and Resectr Tissue Resection Device. The UTRS average annual return since 2021 is shown above.
The Average Annual Return on the UTRS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether UTRS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the UTRS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|